Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have seen revenue climb in recent years thanks to their expertise in one particular area: weight loss drugs. The companies are leaders in this market ...

Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake Jan ...

Evangeline Lilly is sharing an update on her health following an unfortunate accident in May 2025. In an Instagram video posted on Friday, Jan. 2, the 46-year-old "Lost" star shared that she has ...

Jakob Roze, CSCS, is a health writer and high-end personal trainer. He is the founder and CEO of RozeFit, a high-end concierge personal training practice and online blog. Cardio first supports warming ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Over the past few years, Eli Lilly (NYSE: LLY) has ...

Eli Lilly (LLY) submitted an FDA application for orforglipron. The once-daily oral pill maintained weight loss after patients switched from injections. Lilly’s Zepbound achieved 20.2% average weight ...

Eli Lilly said its experimental daily obesity pill helped patients maintain most of their weight loss after switching from injectable drugs like Zepbound. Military lawyer swiftly fired from ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the FDA for approval on Thursday. Eli Lilly’s LLY drug is called orforglipron.

Orforglipron maintains weight loss after switching from injectable GLP-1 drugs Lilly and Novo Nordisk await U.S. regulatory approvals for weight-loss pills FDA may expedite review of Lilly's ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020.

Eli Lilly said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking Wegovy and Zepbound injections in a late-stage trial ...